Eric Benevich insider trades: Neurocrine Biosciences (NBIX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Eric reports to the SEC
Open-market buys and sales
36 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | NBIX | ↓ Sell | 2,154 | $154.61 | $333K | Direct | Sep 10, 2026 (1d) |
| Nov 28, 2025 | NBIX | ↓ Sell | 5,970 | $151.74 | $906K | Direct | Dec 2, 2025 (4d) |
| Feb 13, 2025 | NBIX | ↓ Sell | 2,154 | $116.73 | $251K | Direct | Feb 14, 2025 (1d) |
| Feb 10, 2025 | NBIX | ↓ Sell | 980 | $118.31 | $116K | Direct | Feb 12, 2025 (2d) |
| Jan 31, 2025 | NBIX | ↓ Sell | 1,207 | $152.94 | $185K | Direct | Feb 4, 2025 (4d) |
| Apr 15, 2024 | NBIX | ↓ Sell | 19,818 | $133.36 | $2.6M | Direct | Apr 17, 2024 (2d) |
| Mar 14, 2024 | NBIX | ↓ Sell | 75,000 | $139.38 | $10.5M | Direct | Mar 15, 2024 (1d) |
| Feb 28, 2024 | NBIX | ↓ Sell | 75,000 | $134.69 | $10.1M | Direct | Feb 29, 2024 (1d) |
| Feb 13, 2024 | NBIX | ↓ Sell | 1,098 | $133.01 | $146K | Direct | Feb 15, 2024 (2d) |
| Feb 8, 2024 | NBIX | ↓ Sell | 2,260 | $138.68 | $313K | Direct | Feb 8, 2024 (0d) |
| Jan 31, 2024 | NBIX | ↓ Sell | 1,207 | $140.78 | $170K | Direct | Feb 2, 2024 (2d) |
| Aug 21, 2023 | NBIX | ↓ Sell | 1,600 | $107.40 | $172K | Direct | Aug 23, 2023 (2d) |
| Feb 8, 2023 | NBIX | ↓ Sell | 19,650 | $102.70 | $2.0M | Direct | Feb 8, 2023 (0d) |
| Jan 31, 2023 | NBIX | ↓ Sell | 1,207 | $109.95 | $133K | Direct | Feb 2, 2023 (2d) |
| Jan 6, 2023 | NBIX | ↓ Sell | 400 | $125.00 | $50K | Direct | Jan 10, 2023 (4d) |
| Nov 30, 2022 | NBIX | ↓ Sell | 50,000 | $125.90 | $6.3M | Direct | Dec 1, 2022 (1d) |
| Nov 10, 2022 | NBIX | ↓ Sell | 24,693 | $125.33 | $3.1M | Direct | Nov 10, 2022 (0d) |
| Nov 3, 2022 | NBIX | ↓ Sell | 9,368 | $125.02 | $1.2M | Direct | Nov 4, 2022 (1d) |
| Oct 17, 2022 | NBIX | ↓ Sell | 4,960 | $110.82 | $550K | Direct | Oct 19, 2022 (2d) |
| Feb 8, 2022 | NBIX | ↓ Sell | 5,099 | $80.57 | $411K | Direct | Feb 9, 2022 (1d) |
| Aug 16, 2021 | NBIX | ↓ Sell | 5,628 | $89.62 | $504K | Direct | Aug 18, 2021 (2d) |
| Feb 8, 2021 | NBIX | ↓ Sell | 5,079 | $116.38 | $591K | Direct | Feb 9, 2021 (1d) |
| Jan 26, 2021 | NBIX | ↓ Sell | 5,477 | $120.02 | $657K | Direct | Jan 27, 2021 (1d) |
| Nov 12, 2020 | NBIX | ↓ Sell | 2,257 | $90.71 | $205K | Direct | Nov 16, 2020 (4d) |
| Nov 2, 2020 | NBIX | ↓ Sell | 20,595 | $96.53 | $2.0M | Direct | Nov 4, 2020 (2d) |
| Aug 5, 2020 | NBIX | ↓ Sell | 2,257 | $118.85 | $268K | Direct | Aug 7, 2020 (2d) |
| Apr 24, 2020 | NBIX | ↓ Sell | 1,934 | $99.45 | $192K | Direct | Apr 28, 2020 (4d) |
| Apr 15, 2020 | NBIX | ↓ Sell | 8,632 | $94.65 | $817K | Direct | Apr 17, 2020 (2d) |
| Feb 7, 2020 | NBIX | ↓ Sell | 2,030 | $103.32 | $210K | Direct | Feb 11, 2020 (4d) |
| Feb 6, 2020 | NBIX | ↓ Sell | 3,349 | $102.38 | $343K | Direct | Feb 7, 2020 (1d) |
| Jul 15, 2019 | NBIX | ↓ Sell | 5,835 | $87.44 | $510K | Direct | Jul 17, 2019 (2d) |
| Feb 6, 2019 | NBIX | ↓ Sell | 920 | $83.57 | $77K | Direct | Feb 8, 2019 (2d) |
| Feb 5, 2019 | NBIX | ↓ Sell | 1,357 | $88.01 | $119K | Direct | Feb 6, 2019 (1d) |
| Jun 1, 2018 | NBIX | ↓ Sell | 12,350 | $97.34 | $1.2M | Direct | Jun 5, 2018 (4d) |
| Feb 5, 2018 | NBIX | ↓ Sell | 820 | $83.14 | $68K | Direct | Feb 7, 2018 (2d) |
| Feb 7, 2017 | NBIX | ↓ Sell | 953 | $43.32 | $41K | Direct | Feb 8, 2017 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NBIX insiders
Open-market trades in the last 12 months
About Eric Benevich's insider trades
Eric Benevich is Chief Commercial Officer at Neurocrine Biosciences (NBIX). Since Feb 7, 2017, Eric has reported no open-market purchases and 36 sales worth $47.3M on SEC Form 4. In the last 12 months: 2 sales ($1.2M).
Their filings also include option exercises (17 filings), grants and awards (16 filings), shares withheld for taxes (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NBIX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.